Global Cancer Biopsy Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Global Cancer Biopsy Market Overview

• The Global Cancer Biopsy Market is valued at USD 36 billion, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of cancer globally, the expansion of organized screening programs, and advancements in biopsy technologies such as image-guided, robot-assisted, and next-generation sequencing-based assays. The market is also supported by the growing adoption of personalized medicine, the rising use of molecular profiling and companion diagnostics, and the need for precise, minimally invasive diagnostic tools in oncology.
• Key players in this market include the United States, Germany, and Japan, which dominate due to their advanced healthcare infrastructure, high cancer screening rates, strong reimbursement frameworks, and significant investments in oncology research and development. The presence of leading biotechnology, diagnostics, and pharmaceutical companies in these regions further enhances their market position, supporting rapid adoption of liquid biopsy, digital pathology, and biomarker-driven testing and enabling broad access to cutting-edge biopsy technologies.
• In 2023, the U.S. Food and Drug Administration (FDA) finalized the rule “Medical Devices; Laboratory Developed Tests” issued by the U.S. Food and Drug Administration, which phases in oversight of many in vitro diagnostic tests, including those used as cancer biopsy and liquid biopsy assays, under the Federal Food, Drug, and Cosmetic Act. This regulation introduces a phased compliance framework for premarket review, quality system requirements, and adverse event reporting, with the objective of improving the reliability, analytical performance, and clinical validity of innovative biopsy-related diagnostic devices and thereby supporting more effective cancer diagnosis and treatment decision-making.

Global Cancer Biopsy Market Segmentation

By Product:The product segmentation of the market includes Instruments, Kits and Consumables, and Services. The Instruments segment is currently leading the market due to the increasing adoption of advanced imaging-guided and automated biopsy devices that enhance precision, enable minimally invasive sampling, and reduce procedure time and patient discomfort. Kits and Consumables are also significant, supported by the rising volume of histopathology, cytology, and molecular tests, as well as growing use of reagents and sample preparation kits for tissue and liquid biopsies. Services, while essential, represent a smaller portion of the market as they are often bundled with product offerings and are increasingly integrated into centralized and reference laboratory testing workflows.

By Type:The market is segmented by type into Tissue Biopsies, Needle Biopsies (FNA, Core Needle), Surgical Biopsies, Liquid Biopsies, and Others. Needle Biopsies are the most dominant segment due to their minimally invasive nature, ability to obtain high-quality samples under image guidance, and widespread use across breast, lung, and liver cancers in both inpatient and outpatient settings. Tissue Biopsies also hold a significant share, as histopathological examination of tissue remains the gold standard for definitive cancer diagnosis and grading. Liquid Biopsies are gaining strong traction owing to their non-invasive approach, utility in detecting circulating tumor DNA and other biomarkers, and expanding applications in early detection, minimal residual disease monitoring, and treatment response assessment, which is driving rapid test menu expansion and clinical adoption.

Global Cancer Biopsy Market Competitive Landscape

The Global Cancer Biopsy Market is characterized by a dynamic mix of regional and international players. Leading participants such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., Agilent Technologies, Inc., Siemens Healthineers AG, Hologic, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Abbott Laboratories, Exact Sciences Corporation, Guardant Health, Inc., Foundation Medicine, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., ANGLE plc contribute to innovation, geographic expansion, and service delivery in this space.

Global Cancer Biopsy Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Cancer:The global cancer incidence is projected to reach 19.3 million new cases in future, according to the World Health Organization. This alarming rise in cancer cases is a significant driver for the cancer biopsy market, as early diagnosis is crucial for effective treatment. Countries like the United States report over 1.9 million new cancer cases annually, highlighting the urgent need for advanced diagnostic tools, including biopsies, to manage this growing health crisis effectively.
• Advancements in Biopsy Technologies:The cancer biopsy market is significantly influenced by technological innovations, with the global market for biopsy devices expected to exceed $5.5 billion in future. Innovations such as image-guided biopsies and robotic-assisted techniques enhance accuracy and reduce patient discomfort. Furthermore, the introduction of next-generation sequencing technologies allows for more precise tumor profiling, which is essential for personalized treatment plans, thereby driving demand for these advanced biopsy solutions.
• Rising Demand for Early Cancer Detection:The increasing focus on early cancer detection is a critical growth driver for the biopsy market. In future, it is estimated that over 60% of cancer patients will benefit from early diagnosis, significantly improving survival rates. This trend is supported by healthcare initiatives promoting screening programs, which are expected to increase the number of biopsies performed annually. As a result, the demand for reliable and efficient biopsy procedures continues to grow, further propelling market expansion.

Market Challenges

• High Costs Associated with Biopsy Procedures:The financial burden of biopsy procedures poses a significant challenge, with costs ranging from $1,200 to $3,500 per procedure in developed regions. This high expense can limit access to necessary diagnostic services, particularly in low-income populations. Additionally, the overall healthcare expenditure in the U.S. is projected to reach $4.6 trillion in future, which may strain budgets and lead to reduced funding for essential cancer diagnostics, including biopsies.
• Lack of Skilled Professionals:The cancer biopsy market faces a critical challenge due to a shortage of skilled healthcare professionals. In future, it is estimated that the U.S. will experience a deficit of over 120,000 pathologists and oncologists, which can hinder the timely execution of biopsy procedures. This shortage not only affects the quality of care but also delays diagnosis and treatment, ultimately impacting patient outcomes and market growth in the region.

Global Cancer Biopsy Market Future Outlook

The future of the cancer biopsy market appears promising, driven by ongoing technological advancements and a growing emphasis on personalized medicine. As healthcare systems increasingly adopt liquid biopsy techniques, the market is expected to witness significant transformation. Furthermore, the integration of artificial intelligence in diagnostic processes is anticipated to enhance accuracy and efficiency, paving the way for innovative solutions that cater to the rising demand for early cancer detection and patient-centric care.

Market Opportunities

• Development of Minimally Invasive Techniques:The shift towards minimally invasive biopsy techniques presents a substantial opportunity for market growth. These methods, which reduce patient recovery time and discomfort, are gaining traction, with an expected increase in adoption rates by 30% in future. This trend aligns with the broader healthcare focus on improving patient experiences and outcomes.
• Expansion in Emerging Markets:Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth potential for the cancer biopsy market. With a projected increase in healthcare spending to $1.8 trillion in these regions in future, there is a growing demand for advanced diagnostic tools. This expansion is driven by rising cancer incidence rates and increasing awareness of early detection, creating a favorable environment for market players.